...in vivo Percutaneous absorption, as determined by the cumulative excretion of ractretinoin-induced changes in gene expression regulate skin function are not current evidence suggests that the effectiveness of tretinoin in acne is due...receptors (RAR α, and RAR γ). Tretinoin is a retinoid metabolite of Vitamin A that binds to intracellular receptors (RAR α, and RAR γ). Tretinoin is a retinoid family of compounds, and a metabolite of naturally...Chemically, tretinoin is all-trans-retinoic acid, also known as (all-9-cis)-retinoic acid (also known as all-9-cis-retinoic acid, or all-9-cis-RA).

CLINICAL PHARMACOLOGY
Tretinoin is a retinoid metabolite of Vitamin A that binds to intracellular receptors (RAR α, and RAR γ). Tretinoin is a retinoid family of compounds, and a metabolite of naturally...Chemically, tretinoin is all-trans-retinoic acid, also known as (all-9-cis)-retinoic acid (also known as all-9-cis-retinoic acid, or all-9-cis-RA).

CLINICAL PHARMACOLOGY
Tretinoin is a retinoid metabolite of Vitamin A that binds to intracellular receptors (RAR α, and RAR γ). Tretinoin is a retinoid family of compounds, and a metabolite of naturally...Chemically, tretinoin is all-trans-retinoic acid, also known as (all-9-cis)-retinoic acid (also known as all-9-cis-retinoic acid, or all-9-cis-RA).

REFERENCES
Tretinoin gel, USP (microsphere)

Non-Effects

Topical tretinoin has been shown to be toxic in rabbits when administered 0.35 mg/g/day for 10 days; the maximum human systemic dose applied topically and normalized for total body surface area was 0.5 mg/g/day. In studies on tretinoin gel, USP (microsphere) 0.04%, throughout the treatment period the majority of patients experienced some degree of irritation (itch, burning, or stinging). A transitory feeling of warmth or slight stinging, which may be noted on application.

OVERDOSAGE

Tretinoin gel, USP (microsphere) 0.1% and 0.04% is intended for topical use only. If medication is applied excessively, more rapid or better results will be obtained. However, the medication will be shed along with the skin and may cause irritation. If this occurs, stop using the medication and wash off any excess from the skin.

DOSAGE AND ADMINISTRATION

Tretinoin gel, USP (microsphere) 0.1% and 0.04% should be applied once a day. The medication is intended to be used in the morning, preferably after bathing and before the application of other topical products. Patients treated with tretinoin gel, USP (microsphere) 0.1% or 0.04% may use moisturizers, but should always consult their dermatologist before doing so.

Therapeutic results may be noticed after two weeks, but more than seven weeks of therapy are required before consistent beneficial effects are observed. Patients treated with tretinoin gel, USP (microsphere) 0.1% or 0.04% may use moisturizers, but should always consult their dermatologist before doing so.

Precautions

Tretinoin gel, USP (microsphere) 0.1% normalized for total body surface area, is intended for topical use only. If medication is applied excessively, more rapid or better results will be obtained. However, the medication will be shed along with the skin and may cause irritation. If this occurs, stop using the medication and wash off any excess from the skin.

ADVERSE REACTIONS

Irritation Potential

In studies on tretinoin gel, USP (microsphere) 0.04%, throughout the treatment period the majority of patients experienced some degree of irritation (itch, burning, or stinging). A transitory feeling of warmth or slight stinging, which may be noted on application.

Oral ingestion of large amounts of the drug may lead to the same side effects as those associated with systemic tretinoin, e.g., nausea, vomiting, diarrhea, dizziness, flushing, and skin irritation.

Geriatric Use:

Geriatric Use: Safety and effectiveness in a geriatric population have not been established. Geriatric Use: Safety and effectiveness in a geriatric population have not been established.

Stereoid freedom studies are needed before you see the full benefit. Tretinoin gel, USP (microsphere) is indicated for the treatment of dermatologic conditions associated with acne vulgaris, including comedones, cysts, nodules, and papules. It is also approved for the treatment of actinic keratoses in non-tumor afflicted patients of all ages.

Non-Teratogenic Effects

Topical tretinoin has been shown to be toxic in rabbits when administered 0.35 mg/g/day for 10 days; the maximum human systemic dose applied topically and normalized for total body surface area was 0.5 mg/g/day. In studies on tretinoin gel, USP (microsphere) 0.04%, throughout the treatment period the majority of patients experienced some degree of irritation (itch, burning, or stinging). A transitory feeling of warmth or slight stinging, which may be noted on application.

Oral ingestion of large amounts of the drug may lead to the same side effects as those associated with systemic tretinoin, e.g., nausea, vomiting, diarrhea, dizziness, flushing, and skin irritation.

Geriatric Use:

Geriatric Use: Safety and effectiveness in a geriatric population have not been established. Geriatric Use: Safety and effectiveness in a geriatric population have not been established.

Stereoid freedom studies are needed before you see the full benefit. Tretinoin gel, USP (microsphere) is indicated for the treatment of dermatologic conditions associated with acne vulgaris, including comedones, cysts, nodules, and papules. It is also approved for the treatment of actinic keratoses in non-tumor afflicted patients of all ages.

Non-Teratogenic Effects

Topical tretinoin has been shown to be toxic in rabbits when administered 0.35 mg/g/day for 10 days; the maximum human systemic dose applied topically and normalized for total body surface area was 0.5 mg/g/day. In studies on tretinoin gel, USP (microsphere) 0.04%, throughout the treatment period the majority of patients experienced some degree of irritation (itch, burning, or stinging). A transitory feeling of warmth or slight stinging, which may be noted on application.

Oral ingestion of large amounts of the drug may lead to the same side effects as those associated with systemic tretinoin, e.g., nausea, vomiting, diarrhea, dizziness, flushing, and skin irritation.

Geriatric Use:

Geriatric Use: Safety and effectiveness in a geriatric population have not been established. Geriatric Use: Safety and effectiveness in a geriatric population have not been established.

Stereoid freedom studies are needed before you see the full benefit. Tretinoin gel, USP (microsphere) is indicated for the treatment of dermatologic conditions associated with acne vulgaris, including comedones, cysts, nodules, and papules. It is also approved for the treatment of actinic keratoses in non-tumor afflicted patients of all ages.

Non-Teratogenic Effects

Topical tretinoin has been shown to be toxic in rabbits when administered 0.35 mg/g/day for 10 days; the maximum human systemic dose applied topically and normalized for total body surface area was 0.5 mg/g/day. In studies on tretinoin gel, USP (microsphere) 0.04%, throughout the treatment period the majority of patients experienced some degree of irritation (itch, burning, or stinging). A transitory feeling of warmth or slight stinging, which may be noted on application.

Oral ingestion of large amounts of the drug may lead to the same side effects as those associated with systemic tretinoin, e.g., nausea, vomiting, diarrhea, dizziness, flushing, and skin irritation.

Geriatric Use:

Geriatric Use: Safety and effectiveness in a geriatric population have not been established. Geriatric Use: Safety and effectiveness in a geriatric population have not been established.

Stereoid freedom studies are needed before you see the full benefit. Tretinoin gel, USP (microsphere) is indicated for the treatment of dermatologic conditions associated with acne vulgaris, including comedones, cysts, nodules, and papules. It is also approved for the treatment of actinic keratoses in non-tumor afflicted patients of all ages.